Remedium Capital Partners, LLC SYRE — Spyre Therapeutics Inc

Ownership history in Remedium Capital Partners, LLC  ·  4 quarters on record

AI Ownership Summary

Remedium Capital Partners, LLC reported Spyre Therapeutics Inc (SYRE) in 4 quarterly 13F filings from 2025 Q4 through 2026 Q3. Peak portfolio weight reached 37.77% in 2026 Q3. The latest visible filing shows SYRE at 37.77% of the fund.

This page tracks quarterly shares, estimated market value, portfolio weight, filing dates, and disclosure-aligned stock prices directly from SEC EDGAR 13F filings.

What this SYRE ownership page tells you

This page is designed to answer the real investor question behind a 13F filing: how meaningful was Remedium Capital Partners, LLC's position in Spyre Therapeutics Inc, and how did that conviction change over time? You can read the holding window, peak weight, latest reported size, disclosure timing, and quarter-by-quarter changes without piecing the story together from raw SEC rows.

Freshest filing
Latest Reported Filing
2026 Q3

SYRE was reported at 37.77% of portfolio in the most recent visible filing.

High-water mark
Peak Conviction
37.77% in 2026 Q3

Peak weight helps separate a token disclosure from a real conviction holding the fund genuinely cared about.

Time in book
Holding Window
2025 Q4 to 2026 Q3

Longer holding windows often tell a very different story from short-lived tactical trades or one-quarter experiments.

Decision context
Why It Matters
Position size beats headlines

Knowing that a fund owned a stock is useful. Knowing whether it was a 0.20% placeholder or a true high-conviction position is where the signal actually starts.

How Remedium Capital Partners, LLC held SYRE — position size vs. price
% of Fund (quarterly)
📋 Quarterly Holdings History 4 quarters  ▾
Quarter Action Sold % After 3M Timing Shares Change Chg % % of Fund Mkt Value Filed Price (Filed)
2026 Q3 REDUCED — — — 1,160,620 -303,549 -20.7% 37.77% $103.3M 2026-11-13 $104.00
2026 Q2 REDUCED — — — 1,464,169 -443,158 -23.2% 28.78% $130.0M 2026-08-07 $104.91
2026 Q1 ADDED — — — 1,907,327 +451,096 +31.0% 30.09% $96.2M 2026-05-19 $66.62
2025 Q4 INITIATED — — — 1,456,231 — — 28.03% $47.7M 2026-02-12 $34.84

FAQ About Remedium Capital Partners, LLC and SYRE

These are the practical questions this page is built to answer before you even open the full history table.

How long has Remedium Capital Partners, LLC reported owning SYRE?

Remedium Capital Partners, LLC reported SYRE across 4 quarterly 13F filings, from 2025 Q4 through 2026 Q3.

What was the largest reported SYRE position in Remedium Capital Partners, LLC's portfolio?

The largest reported portfolio weight for SYRE was 37.77% in 2026 Q3.

What is the latest reported SYRE position on this page?

The most recent filing on this page is 2026 Q3, when Remedium Capital Partners, LLC reported 1,160,620 shares, equal to 37.77% of portfolio, with an estimated market value of $103.3M.

What does the chart on this SYRE ownership page compare?

The chart compares Remedium Capital Partners, LLC's quarterly SYRE portfolio weight with the stock's indexed share price, so you can see whether the fund was building, trimming, or holding the position as price moved.

How well did Remedium Capital Partners, LLC time their SYRE position?

Based on 13F filing dates vs. subsequent SYRE price moves, Remedium Capital Partners, LLC correctly timed 3 out of 3 reported position changes (100%). The annualised alpha on SYRE relative to SPY over the holding period was +271.2%.

← Back to Remedium Capital Partners, LLC Holdings